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N potential disadvantage of the clinical use of G-CSF in systemic inflammatory diseases is the potentiation of neutrophil-ORMAL NUMBERS and function of neutrophils are necessary for a successful host defense against a variety of invading microbes. 1 On the other hand, systemic in-mediated organ damage. Endotoxin administration to humans is a widely accepted flammatory responses are associated with sequestration of activated neutrophils in organs, which may lead to tissue model to study early inflammatory host responses to sepsis in humans and results in the release of cytokines and activa-destruction through release of oxygen radicals and proteolytic enzymes. [2] [3] [4] The mechanism of granulocyte adherence tion of leukocytes. Knowledge of the effects of G-CSF on lipopolysaccharide (LPS)-induced cytokine release in hu-to the vascular endothelium has been well characterized and consists of selectin-mediated rolling, 5-7 followed by adhesion mans is limited. In recent studies, ex vivo stimulations of whole blood from G-CSF-treated humans showed enhanced dependent on interactions of b 2 integrins and intercellular adhesion molecule-1 (ICAM-1). 8 Chemotactic agents, such IL-1 receptor antagonist (IL-1ra) and soluble TNF receptor (sTNFR) concentrations. 29 In Salmonella abortus equi endo-as interleukin-8 (IL-8) and platelet activating factor, are involved in subsequent trans-endothelial cell migration. 9, 10 The toxemia in humans, G-CSF administered 12 hours before endotoxin increased LPS-induced proinflammatory and anti-importance of these interactions is underscored by the finding that, in animal models of endotoxemia, interference with inflammatory cytokine release. 30 To date, the effects of different timing of administration of G-CSF on cytokine release the neutrophil-endothelial interaction, by administration of integrin-targeted antibodies, ameliorated end-organ damage, and neutrophil function in human endotoxemia in vivo have not been reported. We therefore designed a controlled, cross-in particular lung injury. 11 Granulocyte colony-stimulating factor (G-CSF) is an 18-kD glycoprotein that increases pe-over, placebo-controlled study of low-dose human endotoxemia to evaluate the effects of G-CSF administered 2 hours ripheral blood neutrophil counts by stimulating proliferation and shortening bone marrow transit time, thereby reducing before LPS challenge or 24 hours before LPS challenge on endotoxin-induced cytokine release, circulating granulocyte the neutrophil storage pool. 12 In addition, G-CSF improves phagocytosis, delays apoptosis, increases chemotaxis and cy-and monocyte counts, granulocyte degranulation, and extotoxicity in vitro, and causes upregulation of the expression of CD11b, CD18, and CD67 by human granulocytes in vivo. [13] [14] [15] [16] [17] In chemotherapy-treated patients, administration of punctures at 024 (group 2) or 02 and 01 (group 1) and subsequently pression of adhesion molecules. Furthermore, endotoxin-inat 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10, and 20 hours relative to endotoxin duced granulocyte accumulation in the lungs and liver was administration. For leukocyte and differential counts, blood was colquantitatively determined by radionuclide dynamic granulolected in tubes containing EDTA (K 3 ) (15%) and assessed by flow scintigraphy. cytometry (Technicon H1 system; Technicon Instruments, Tarrytown, NY). Blood for cytokine assays was collected in vacutainer MATERIALS AND METHODS tubes (Becton Dickinson, Mountain View, CA); after clotting, samples were centrifuged at 2,000g for 20 minutes at room temperature Study group. The study was approved by the research and ethical and serum was stored at 020ЊC until assays were performed committees of the Academic Medical Center and written informed batchwise. Cytokine concentrations were determined using specific consent was obtained from all volunteers. A total of 16 healthy male enzyme-linked immunosorbent assays (ELISAs): TNF, sTNFR I, subjects (mean age, 23 years; range, 19 to 32 years) was studied. and sTNFR II (Medgenix Diagnostic, Brussels, Belgium); G-CSF Medical history, physical examination, and routine laboratory examiand IL-1ra (Quantikine; R&D Systems, Abingdon, UK); and IL-6 nation were unremarkable in all volunteers. The study subjects were and IL-8 (Central Laboratory of the Netherlands Red Cross Blood nonsmokers and did not use any medication, and their ECG and Transfusion Service CLB, Amsterdam, The Netherlands). The ELIchest x-ray results were normal. Volunteers were excluded from SAs measure immunologic activity and may not represent biologiparticipation in the study if they had had any febrile disease in the cally active concentrations. 2 weeks preceding the study.
Blood for elastase a 1 -antitrypsin complexes (elastase) and lacto-Study design. The study was designed as a double-blind, crossferrin assays was obtained in tubes containing 10 mmol/L EDTA, over, randomized, placebo-controlled study in which all volunteers 10 mmol/L benzamidine hydrochloride hydrate 98%, and 100 mg/ were treated with endotoxin on two occasions, with a wash-out mL soybean trypsin inhibitor. Circulating levels of elastase and lacperiod of 6 weeks. On one occasion the endotoxin treatment was toferrin were measured by radioimmunoassay (RIA). 32 combined with placebo and on the other occasion with G-CSF. The
FACScan analysis of granulocytes. Blood for flow cytometry volunteers were randomized into two groups of eight subjects. Group was obtained at 024 (group 2) or 02 (group 1), 0, 1, 2, 4, and 6 1 received either placebo or G-CSF treatment, administered intravehours relative to endotoxin challenge in EDTA (K 3 ) (15%) tubes nously, starting 2 hours before endotoxin; group 2 received either and immediately placed on ice. Erythrocytes were lysed with iceplacebo or G-CSF treatment administered subcutaneously 24 hours cold isotonic NH 4 Cl solution (155 mmol/L NH 4 Cl, 10 mmol/L before endotoxin administration. These two time points were based KHCO 3 , 0.1 mmol/L EDTA, pH 7.4) for 20 minutes. Cells were on results from a pilot study (Pajkrt et al, unpublished data) in which centrifuged (600g for 10 minutes at 4ЊC) and residual erythrocytes it was shown that, upon LPS stimulation of whole blood of G-CSFwere lysed for 5 minutes. The remaining cells were washed twice treated volunteers, TNF-a production was reduced at 2 and 24 hours in cold phosphate-buffered saline (PBS) and subsequently fixed in after G-CSF administration. The study drug G-CSF (Amgen, Thouice-cold PBS containing 1% bovine serum albumin (BSA), 0.3 sand Oaks, CA) was provided as a pyrogen-free, colorless, clear mmol/L EDTA, 0.01% sodium azide, and 0.1% paraformaldehyde fluid in a glass vial containing 300 mg/mL recombinant human Gat a final concentration of 5 1 10 6 cells/mL. CSF. To ensure high circulating G-CSF levels at the time of endo-
The antibodies used were directed against CD11b, CD18, CD33, toxin administration, group 1 received the total dose of 5 mg/kg as and CD67 (CLB-mon-gran/1,B2, CLB-LFA-1/1,54, CLB-MD33.6, a 30-minute infusion through an intravenous line; group 2 received and CLB-B13.9, respectively; Central Laboratory of the Netherlands 5 mg/kg G-CSF subcutaneously, the usual route of administration.
Red Cross Blood Transfusion Service CLB). Control IgG 1 , IgG 2 , The placebo solution was identical in appearance and contained and L-selectin (Leu-8) were obtained from Becton Dickinson. After isotonic saline.
the addition of the primary monoclonal antibody (MoAb) to the cell The Escherichia coli endotoxin preparations used in this study, suspension, the cells were incubated for 30 minutes at 4ЊC and lot EC-5 (D. Hochstein, Bureau of Biologics, Food and Drug Adminwashed twice in cold PBS containing 1% BSA, 0.3 mmol/L EDTA, istration, Bethesda, MD; group 1) and lot G (United States Pharmaand 0.01% sodium azide. Subsequently, R-phycoerythrin (RPE)-concopeia Convention Inc, Rockville, MD; group 2), were administered jugated F(ab) 2 fragments of rabbit-antimouse Igs (R 0439; Dako as an intravenous injection (4 ng/kg) over 1 minute 31 
hours after
A/S, Glostrup, Denmark) were added and cells were incubated for the start of G-CSF or placebo infusion (group 1) or 24 hours after another 30 minutes at 4ЊC. After two washes, granulocytes were subcutaneously administered G-CSF or placebo. In group 2, lot G gated by forward scatter and side scatter using a FACScan (Becton was used because of lack of availability of lot EC-5. The two endo-Dickinson) and 10,000 cells were counted. After subtracting control toxin preparations are both smooth forms of endotoxin from the IgG fluorescence, specific antibody binding was expressed as mean same serotype and show similar endotoxin activity as measured by fluorescence intensity (MFI). Data are provided as the percentage the Limulus amebocyte lysate assay (data not shown). Each group changes from pretreatment values obtained at either 24 hours (group received the same endotoxin during the two treatment periods.
2) or 2 hours (group 1) before endotoxin challenge (baseline). The volunteers were confined throughout the two study periods Radiolabeling of granulocytes. All procedures were performed at a clinical research unit. During these periods, they were under in a laminar flow chamber using sterile, pyrogen-free glassware and continuous supervision of at least two physicians. Complete emerinstruments. Five hours before the endotoxin administration, 100 gency and resuscitation equipment was immediately available. Heart mL of venous blood was collected from each volunteer into 20% rate was monitored continuously during the first 8 hours after endo-(vol/vol) acid citrate dextrose (3.2%) and 6% (vol/vol) Hydroxyethyl toxin infusion, and blood pressure and oxygen saturation were moni-Ether Starch (Fresenius, 's Hertogenbosch, The Netherlands). After tored each for 30 minutes using a Dinamap device (Criticon, Tampa, sedimentation at room temperature for about 45 minutes, the super-FL) during the first 8 hours after endotoxin administration. Oral natant, which was composed of leukocyte-rich plasma, was centritemperature and respiratory rate were assessed at the same time fuged at 200g for 10 minutes and the pellet was resuspended in 3 points. Adverse events were registered throughout the confinement mL autologous plasma. The granulocytes were isolated by Percoll periods by a clinical symptom score. Adverse events were scored density gradient centrifugation (Pharmacia, Woerden, The Netherby incidence and severity (1 as weakly, 2 as moderately, and 3 as lands) at 200g for 30 minutes. The pellet, containing pure granuloseverely present).
Sampling and assays. Blood was collected by separate veni-cytes, was suspended in 10 mL with saline and centrifuged at 200g 2, G-CSF pretreatment reduced LPS-induced IL-6 levels Dynamic granuloscintigrams. Scintigraphic images in group 1 were continuously recorded from 5 minutes before endotoxin admin-from peak concentrations of 8.11 { 6.22 to 2.65 { 0.74 ng/ istration until 120 minutes after endotoxin administration. In group mL (P Å .4; Fig 2C) . In group 1, G-CSF pretreatment en- Leukocyte counts. As shown in Fig 4A, a 2 -hour pre-Clinical symptoms and signs. Injection of the endotoxin treatment with G-CSF enhanced both LPS-induced leukopepreparations caused similar flu-like symptoms such as headnia (from nadir levels of 3.1 { 0.4 1 10 9 /L to 2.6 { 0.1 1 ache, chills, nausea, vomiting, and fever. Administration of 10 9 /L) and leukocytosis (from peak levels of 16.4 { 1.7 1 G-CSF did not induce any side effects. All volunteers were 10 9 /L to 21.7 { 1.1 1 10 9 /L; P õ .001). In group 2, G-CSF symptom-free within 20 hours after endotoxin challenge. In pretreatment increased leukocyte concentrations to 24.1 { group 1, G-CSF treatment enhanced the endotoxin-induced 1.0 1 10 9 /L at t Å 0 hours (P õ .001 in time) and again chills and headache, whereas in group 2, G-CSF pretreatment enhanced LPS-induced leukopenia (from nadir concentrahad no effect on LPS-induced chills and headache. As shown tions of 3.1 { 0.4 1 10 9 /L to 2.9 { 0.7 1 10 9 /L) and in Fig 1, G -CSF pretreatment increased the LPS-induced leukocytosis (from peak concentrations of 15.6 { 1.1 1 10 9 / increase in heart rate (peak levels: group 1, 98 { 4 v 101 { L to 18.3 { 1.2 1 10 9 /L; P õ .001). Changes in neutrophil 4 beats/min, P õ .001; group 2, 93 { 4 v 98 { 45 beats/ counts mimicked changes in total leukocyte counts, as shown min, P Å .048). In both groups, the LPS-induced increase in Fig 4B. In group 1, G-CSF decreased the LPS-induced in temperature was enhanced by G-CSF, although not sigreduction in monocyte counts (from mean levels of 0.04 { nificantly. G-CSF had no effect on LPS-elicited changes in 0.01 1 10 9 /L to 0.03 { 0.01 1 10 9 /L) and augmented the mean arterial pressure. subsequent increase (from peak concentrations of 0.71 { Cytokines. In group 1, administration of G-CSF caused 0.03 1 10 9 /L to 1.14 { 0.14 1 10 9 /L; P õ .001). In group an increase in mean serum G-CSF levels to 229.50 { 16. 33 2, G-CSF pretreatment increased monocyte counts to 1.02 ng/mL 1 hour after G-CSF administration, decreasing to { 0.12 1 10 9 /L at t Å 0 hours (P õ .001 in time) and baseline values thereafter (P õ .001). In group 2, G-CSF enhanced LPS-induced monopenia (from mean levels of 0.06 concentrations of 0.65 { 0.06 ng/mL were detected just { 0.02 1 10 9 /L to 0.04 { 0.01 1 10 9 /L) and monocytosis before LPS challenge, further increasing to 4.37 { 1.00 ng/ mL at 4 hours after LPS challenge (P Å .75; Fig 2A) 10 9 /L; P õ .001; Fig 4C) . Neither treatment regimen had 400.8% { 176.0% to 414.1% { 71.9% (group 2, P Å .7; Fig 6C) . Neutrophil L-selectin expression showed a variable, any effect on endotoxin-induced changes in lymphocyte counts (data not shown).
nonsignificant change after endotoxin administration. G-CSF pretreatment resulted in a significant downregulation of L-Neutrophil degranulation and expression of cell surface markers. Figure 5A shows that, in both groups, G-CSF selectin during the first 2 hours after endotoxin administration, reaching a nadir at t Å 2 hours of 49.1% { 10.9% pretreatment induced release of elastase before endotoxin administration (142.8 { 36.7 ng/mL in group 1 and 168.0 (group 1, P Å .001) and of 45.4% { 20.9% (group 1, P Å .03; Fig 6D) . { 8.4 ng/mL in group 2; P Å .001 in time) and augmented the LPS-induced mean peak elastase release (in group 1,
Dynamic granuloscintigrams. Figure 7 shows that endotoxin administration caused an increase in radioactivity in from 195.1 { 22.3 to 347.9 { 23.8 ng/mL, P õ .001; and in group 2, from 278.3 { 33.8 to 399.6 { 23.8 ng/mL, P Å the lungs up to 120.7% { 10.3% (group 1) and 117.9% { 12.6% (group 2; P õ .001 in time for each). This increase .013). G-CSF pretreatment resulted in an increase of lactoferrin concentrations at t Å 0 hours (644.5 { 172.7 ng/mL in of radiolabeled granulocytes into the lungs was completely blocked by both G-CSF treatment regimens (group 1, P õ group 1 and 226.14 { 19.1 ng/mL in group 2; P õ .001 in time) and further boosted endotoxin-induced release (in .001; group 2, P Å .007; Fig 7A) . In group 1, accumulation of radiolabeled granulocytes in the liver peaked after endotoxin group 1, from 645.9 { 112.1 to 2,328.8 { 371.3 ng/mL; and in group 2, from 539.7 { 74.2 to 1,573.3 { 174.0 ng/ administration to 114.7% { 4.0% (P Å .027 in time) and was significantly reduced by G-CSF pretreatment (P Å .011). mL; P õ .001 for each; Fig 5B) .
As shown in Fig 6A and B, a 2 -hour pretreatment with In group 2, only a modest increase in granulocyte accumulation in the liver was observed to 108.6% { 4.1% (P Å .3). G-CSF significantly augmented LPS-induced increases of neutrophil CD11b from 262.8% { 46.5% to 364.9% { In this group, G-CSF pretreatment modestly enhanced LPSinduced increase in radioactivity in the liver region (P Å 61.2% (P Å .07) and modestly augmented LPS-induced increases in CD18, from 142.8% { 21.9% to 212.6% { 56.7% .27; Fig 7B) . No accumulation in the spleen region was observed after endotoxin administration (data not shown). (P Å .4). In group 2, G-CSF also enhanced, although not significantly, LPS-induced increases of neutrophil CD11b The results of this study show that G-CSF exerts different effects on cytokine release in human endotoxemia when 56.6% (CD18; P Å .46 and P Å .45, respectively). In both groups, G-CSF pretreatment enhanced LPS-elicited in-administered intravenously 2 hours and subcutaneously 24 hours before endotoxin. Administered 2 hours before LPS creases in CD67 expression on neutrophils from 187.9% { 33.1% to 455.0% { 123.1% (group 1, P Å .03) and from challenge, G-CSF boosted the release of TNF, IL-6, IL-8, IL-1ra, and sTNFR I and II, whereas G-CSF, when adminis-inflammatory responses seen in septic patients. It should be noted that the endotoxin administered in group 1 and group tered 24 hours before endotoxin, significantly reduced the release of IL-8 and modestly attenuated systemic TNF and 2 differed (lot EC-5 and lot G, respectively), which may explain, at least in part, why, in general, the inflammatory IL-6 levels. Furthermore, the 24-hour pretreatment importantly induces IL-1ra and sTNF receptor release and further responses observed in group 2 during endotoxemia were more pronounced. However, because of the cross-over de-enhanced LPS-induced increase in sTNFR I and II, but did not enhance LPS-induced IL-1ra concentrations. Despite sign of the study, the effects of different timing of G-CSF administration can be compared. The effects of G-CSF on these diverse effects on cytokine release, both G-CSF treatment regimens augmented neutrophil activation and in-endotoxin-induced cytokine release are in accordance with previous animal studies of infection and sepsis, 23-25 which creased granulocyte adhesion molecule expression. Nonetheless, G-CSF completely blocked the LPS-induced showed that G-CSF improved survival rate and attenuated the release of TNF-a. 23 Furthermore, a human study showed granulocyte accumulation in lungs when administered 2 hours before LPS challenge, and also blocked accumulation that, upon ex vivo stimulation with LPS of whole blood drawn 24 hours after G-CSF administration, increased IL-in the liver.
Endotoxin administration to humans elicits a systemic in-1ra and sTNFR I and II levels were observed in the G-CSFtreated group in comparison with placebo-treated subjects. 29 flammatory response, characterized by release of inflammatory cytokines and activation of neutrophils, 34, 35 and is often
In another study of human endotoxemia, G-CSF, when administered 12 hours before LPS challenge, increased the used as a model to study early host responses to sepsis. However, the inflammatory responses seen after endotoxin release of both proinflammatory and anti-inflammatory cytokines. 30 In our study, we clearly showed that, by delaying injection into healthy volunteers may largely differ from the AID Blood 0020 / 5h3b$$$382 07-15-97 14:49:36 blda WBS: Blood LPS challenge after G-CSF, an excessive proinflammatory even before administration of endotoxin, which is in accordance with previously reported data. 12,17 IL-8 can increase host response can be altered into a more anti-inflammatory response. However, although these effects of G-CSF on cyto-CD11b/CD18 expression in vitro, 37 but it seems unlikely that the enhancement of upregulation of CD11b and CD18 by kine release in human endotoxemia seem clear, the biologic relevance of these observations needs to be evaluated in G-CSF during endotoxemia is mediated by IL-8, for in group 2, reduced IL-8 levels were found in conjunction with en-patients with acute infection and sepsis.
To ensure high G-CSF concentrations at the time of LPS hanced CD11b/CD18 expression on neutrophils. However, increased b 2 integrin expression may have resulted from challenge in group 1, G-CSF was administered intravenously, whereas in group 2 the usual route of administration enhanced elastase release that was caused by both G-CSF treatment regimens 38 and that preceded b 2 integrin upregula-was used. An explanation for the different effect of G-CSF on cytokine release in human endotoxemia might therefore tion. Both G-CSF and endotoxin are known to influence the be that, in group 1, high systemic G-CSF levels were found at the time of LPS challenge, whereas in group 2, only numbers of circulating neutrophils and monocytes. 12, 31 In human volunteers, endotoxin causes a decrease in leukocyte modest elevation in G-CSF concentrations were found at the time of LPS challenge. However, the precise mechanism of counts followed by a leukocytosis. After endotoxin challenge, granulocytes accumulated in the lung and liver region, how G-CSF increases or reduces cytokine release in human endotoxemia needs to be elucidated.
peaking at 90 minutes (group 1) and 105 minutes (group 2) after endotoxin challenge. It is not clear why no significant Administration of G-CSF to healthy volunteers mimicked the effect of endotoxin on neutrophils and resulted in the granulocyte accumulation in the liver was observed in group 2. Surprisingly, although G-CSF pretreatment did not pre-release of elastase and lactoferrin and upregulation of the membrane expression of CD11b, CD64, and CD67. 12,17, 36 vent endotoxin-induced early neutropenia, it completely prevented the endotoxin-induced accumulation of neutrophils in The data from the present study indicate that G-CSF, when administered either 2 or 24 hours before endotoxin challenge, the lungs within 2 hours after LPS challenge. These findings underscore the fact that low circulating neutrophil numbers amplified endotoxin-induced neutrophil activation. This effect of G-CSF was, at least in part, a direct consequence of do not automatically indicate increased neutrophil accumulation in specific organs, such as lungs and liver. The blockage stimulation of neutrophils by G-CSF, because both G-CSF pretreatments caused the release of elastase and lactoferrin, of neutrophil accumulation in the lungs occurred under oth-AID Blood 0020 / 5h3b$$$383 07-15-97 14:49:36 blda WBS: Blood erwise proadhesive conditions, ie, in the presence of in-thelial transmigration. A potential confounding factor in interpreting the granuloscintiscan data is the fact that both creased CD11b and CD18 expression on neutrophils. The Tc-radiolabeling technique used in this study does not allow endotoxin and G-CSF alter the neutrophil population by causing rapid mobilization of young forms from the bone discrimination between neutrophil retention as a consequence of aspecific trapping, specific adhesion, or transendo-marrow. Because the neutrophil labeling occurred ex vivo 
